Pulmonx Corporation (LUNG) is a Medical - Devices company in the Healthcare sector, currently trading at $1.42. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is LUNG = $4 (+181.7% upside).
Valuation: LUNG trades at a trailing Price-to-Earnings (P/E) of -1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.04.
Financials: revenue is $90M, +19.3%/yr average growth. Net income is $54M (loss), growing at +2.8%/yr. Net profit margin is -59.7% (negative). Gross margin is 74.2% (-0.1 pp trend).
Balance sheet: total debt is $56M against $54M equity (Debt-to-Equity (D/E) ratio 1.04, moderate). Current ratio is 5.07 (strong liquidity). Debt-to-assets is 43.6%. Total assets: $129M.
Analyst outlook: 4 / 9 analysts rate LUNG as buy (44%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 63/100 (Pass), Past 0/100 (Fail), Health 50/100 (Partial), Moat 46/100 (Partial), Future 52/100 (Partial), Income 10/100 (Fail).
